Quarry LP Increases Stock Holdings in AngioDynamics, Inc. (NASDAQ:ANGO)

Quarry LP lifted its position in AngioDynamics, Inc. (NASDAQ:ANGO) by 40.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,518 shares of the medical instruments supplier’s stock after buying an additional 2,471 shares during the quarter. Quarry LP’s holdings in AngioDynamics were worth $66,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. CWM LLC lifted its holdings in shares of AngioDynamics by 981.3% in the third quarter. CWM LLC now owns 9,732 shares of the medical instruments supplier’s stock worth $76,000 after buying an additional 8,832 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of AngioDynamics in the third quarter worth about $86,000. SG Americas Securities LLC purchased a new stake in AngioDynamics in the third quarter valued at approximately $103,000. Mackenzie Financial Corp purchased a new stake in AngioDynamics in the second quarter valued at approximately $80,000. Finally, AE Wealth Management LLC purchased a new stake in AngioDynamics in the second quarter valued at approximately $87,000. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Price Performance

Shares of NASDAQ ANGO opened at $7.00 on Monday. AngioDynamics, Inc. has a one year low of $5.26 and a one year high of $8.25. The firm’s 50 day simple moving average is $6.84 and its two-hundred day simple moving average is $6.86. The stock has a market capitalization of $284.41 million, a P/E ratio of -1.15 and a beta of 0.68.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings results on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The business had revenue of $67.50 million for the quarter, compared to analysts’ expectations of $67.93 million. During the same period last year, the business earned ($0.12) earnings per share. The business’s quarterly revenue was down 14.2% on a year-over-year basis. As a group, equities analysts expect that AngioDynamics, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling at AngioDynamics

In other news, CEO James C. Clemmer bought 20,000 shares of the business’s stock in a transaction dated Monday, October 7th. The shares were purchased at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the completion of the acquisition, the chief executive officer now owns 681,582 shares of the company’s stock, valued at approximately $4,109,939.46. This trade represents a 3.02 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have acquired 22,568 shares of company stock worth $135,847 over the last ninety days. Insiders own 5.40% of the company’s stock.

Analysts Set New Price Targets

ANGO has been the topic of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 target price on shares of AngioDynamics in a research note on Friday, October 4th. Canaccord Genuity Group lowered their target price on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th.

AngioDynamics Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.